Comment by elcritch

Seems like a very interesting approach, even if it’s early stage.

> Many tumor types are not PD-l1 positive. > Doxy is an ancient SOC chemo. This is a nothing burger.

Meh the research didn’t say those were state of the art, but that they were “common” treatments. In other words a baseline for a presumably cheap and well studied animal surrogate.

> CAR-T is ahead of the game, and will be the ultimate winner here as it grows to scale.

Last I read up on it last year CAR-T treatments struggled with solid mass tumors.

Many cancers don’t have unique proteins for CAR-T to target (similar to the pd-l1 issue).

Then CAR-T struggles getting the modified T cells into the solid mass tumors en masse. Interestingly this approach actually makes use of the tumor environment rather than be hindered by it.